Specifically in glioblastoma, various pharmacological approaches to limit TGF-β pathway activity have been explored, based on the putative role of TGF-β in migration, invasiveness, angiogenesis and immunosuppression. The gene discussed is TGFB1; the disease is glioblastoma.